Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 17/20 | 0.74 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.74 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9884635 | 0.86 | CXCR4 (0.64) | CXCR4CXCL12 | |
| SCHEMBL22175466 | 0.83 | CXCR4 (0.54) | CXCR4CXCL12 | |
| SCHEMBL9884633 | 0.83 | CXCR4 (0.60) | CXCR4CXCL12 | |
| SCHEMBL22175387 | 0.81 | CXCR4 (0.57) | CXCR4CXCL12 | |
| SCHEMBL9885528 | 0.79 | CXCR4 (0.85) | CXCR4CXCL12HRH3 | |
| SCHEMBL13683806 | 0.79 | CXCR4 (0.61) | CXCR4CXCL12 | |
| SCHEMBL13683819 | 0.79 | CXCR4 (0.57) | CXCR4CXCL12 | |
| SCHEMBL9884646 | 0.78 | CXCR4 (0.60) | CXCR4CXCL12 | |
| SCHEMBL9884628 | 0.78 | CXCR4 (0.60) | CXCR4CXCL12 | |
| SCHEMBL22175399 | 0.77 | CXCR4 (0.58) | CXCR4CXCL12HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1890703-B1 | PYRIMIDINE COMPOUNDS AS CHEMOKINE RECEPTORS INHIBITORS | TAIGEN BIOTECHNOLOGY CO LTD (TW) | 2016-05-11 | — | — | EP | disclosed |
| US-8193206-B2 | Pyrimidine compounds | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2012-06-05 | — | — | US | disclosed |
| US-8193206-B2 | Pyrimidine compounds | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2012-06-05 | — | — | US | disclosed |
| US-7589197-B2 | Pyrimidine compounds | TAIGEN BIOTECHNOLOGY (TW) | 2009-09-15 | — | — | US | disclosed |
| US-7589197-B2 | Pyrimidine compounds | TAIGEN BIOTECHNOLOGY (TW) | 2009-09-15 | — | — | US | disclosed |
| US-20090143302-A1 | PYRIMIDINE COMPOUNDS | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2009-06-04 | — | — | US | disclosed |
| US-20090143302-A1 | PYRIMIDINE COMPOUNDS | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143302-A1 | PYRIMIDINE COMPOUNDS | TYMS, TYMP, HPRT1 | CXCR4 247/4885CXCL12 109/4885HRH3 1540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.